Investigation of Neurons and Microglia from APOE3 Induced Pluripotent Stem Cells using Data-Independent Acquisitions on a ZenoTOF 7600

  1. Jordan B. Burton
  2. Tyne McHugh
  3. Charles A. Schurman
  4. Joanna Bons
  5. Maria Sanchez
  6. Lisa M. Ellerby
  7. Birgit Schilling
0 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Induced pluripotent stem cell (iPSC)-derived neurons and microglia are valuable human models for studying neurodegenerative diseases. Specifically, the apolipoprotein E4 ( APOE4 ) gene is a major genetic risk factor for late-onset Alzheimer’s disease. Apolipoprotein E ( APOE ) alleles E2, E3 and E4 can be beneficial, neutral, or increase the risk of Alzheimer’s disease (AD). Here, we developed a proteomic workflow using data-independent acquisitions to provide a quantitative mass spectrometric proteome analysis, and proteomic screening assays for brain-specific cell types derived from iPSC. Protein groups were quantified in APOE3 neurons and microglia, respectively, with ∼80% overlap. Cell type-specific markers and enriched pathways reflected the specialized functions of each cell type, such as synaptic signaling in neurons and immune and inflammatory responses in microglia. The neuron-specific markers included proteins APP, CALB1, CALB2, DLGs, GAP43, NEFL, MAPs; while microglial markers included proteins AIF1, CDs, MMP9, and ITGAM. Ultimately, the combination of robust iPSC differentiation and sensitive proteomic screening assays described here provides a valuable platform for probing the cellular mechanisms underlying neurological disorders.

Significance

The quantification of dysregulated proteins and pathways in patient-derived neurons and microglia can provide insights into disease etiology and progression. More broadly, this DIA approach enables deep proteome profiling of unique iPSC-derived cell models, increasing their utility for investigating disease biology and therapeutic development. We focused on iPSC models from two important cell types of the brain, excitatory neurons and microglia. We integrated the proteomes of these two cell types. These tools provide robust biological and mass spectrometric screening tools for future therapeutic interventions using disease-relevant human brain cell types or brain organoid models.

Graphical abstract

<fig id="ufig1" position="float" orientation="portrait" fig-type="figure"> <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="686128v1_ufig1" position="float" orientation="portrait"/> </fig>

Highlights

  • Presentation of a proteomic workflow using data-independent acquisitions to monitor and screen proteomes of iPSC-derived brain cell types.

  • Quick MS Assays to determine protein profiles of iPSC-derived neurons and microglia.

  • Characterization of different cell type proteomes from APOE3 iPSCs.

  • Revealing of neuron-specific markers and microglia-specific markers by mass spectrometry.

  • Step-by-step instructions for the set-up of the DIA-MS assays

Related articles

Related articles are currently not available for this article.